Overview

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
A study to examine the combination of temsirolimus and Caelyx® (chemotherapeutic) in advanced or recurrent breast, endometrial and ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Treatments:
Doxorubicin
Everolimus
Liposomal doxorubicin
Sirolimus